Quantcast

Latest CancerVax Stories

2011-06-02 14:31:03

First cancer vaccine to show improved response rate A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to research led by scientists from The University of Texas MD Anderson Cancer Center and Indiana University Health Goshen Center for Cancer Care. The findings, published in the June 2 New England Journal of Medicine, mark the first vaccine...

2011-04-11 06:00:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). The initial year 1...

2011-03-28 08:21:53

(Ivanhoe Newswire--) There could soon new treatment for one of the most deadly forms of cancer, thanks to a study from the University of East Anglia and Children's Hospital Boston. Melanoma, the most aggressive form of skin cancer, affects the pigment cells in skin. More than 10,000 patients every year are diagnosed with melanoma in the United Kingdom, and unlike other cancers, the number of people diagnosed every year is on the rise. Melanoma is treatable when caught early, but if it is...

f2d1d174e9ad266b2a3df2720b6258b21
2011-03-26 08:45:00

A drug from Bristol-Myers Squibb Co. shown to help prolong the lives of people suffering from advanced skin cancer has been approved by the US Food and Drug Administration on Friday.The injectable drug, called Yervoy (ipilimumab), is used for late-stage melanoma. Bristol-Myers Squibb aims to use the drug to harness the body's immune system to target and attack melanoma tumors."Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live...

2011-02-09 06:00:00

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, presented results from preclinical studies with TRX518, a first-in-class immunomodulatory agent for the treatment of cancer. TRX518 is a monoclonal antibody reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's anti-tumor...

2010-12-14 06:00:00

CAMBRIDGE, Mass., Dec. 14, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells. The Phase 1 trial will...

2010-12-01 06:00:00

CAMBRIDGE, Mass. and NEW YORK, Dec. 1, 2010 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) -- a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research -- today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody...

2010-09-28 05:28:00

DALLAS, September 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Research Report in its store. Browse the complete Report on: http://www.reportsandreports.com/reports/33665-emerging-cancer-vaccines- forecasts-developments-and-pipeline-an.html Search More Than 50000 Market Research Reports at ReportsandReports (http://www.reportsandreports.com/) Browse All Kalorama...

2010-09-20 06:59:00

NESS ZIONA, Israel, September 20, 2010 /PRNewswire-FirstCall/ -- NasVax (TASE: NSVX) announces that it has initiated recruitment and dosing in a Phase 2a clinical trial for oral anti-CD3 (aCD3) monoclonal antibody (MAb) immunotherapy. This study is being conducted at Hadassah Medical Center - Hebrew University in Jerusalem Israel in subjects with nonalcoholic steatohepatitis (NASH), a serious inflammatory disease of the liver, and including those with metabolic syndrome. This Phase 2a...

2010-08-17 07:00:00

SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.